These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

360 related items for PubMed ID: 12124326

  • 1. Cyclooxygenase-2 inhibitor treatment enhances photodynamic therapy-mediated tumor response.
    Ferrario A, Von Tiehl K, Wong S, Luna M, Gomer CJ.
    Cancer Res; 2002 Jul 15; 62(14):3956-61. PubMed ID: 12124326
    [Abstract] [Full Text] [Related]

  • 2. Celecoxib and NS-398 enhance photodynamic therapy by increasing in vitro apoptosis and decreasing in vivo inflammatory and angiogenic factors.
    Ferrario A, Fisher AM, Rucker N, Gomer CJ.
    Cancer Res; 2005 Oct 15; 65(20):9473-8. PubMed ID: 16230411
    [Abstract] [Full Text] [Related]

  • 3. A selective cyclooxygenase-2 inhibitor, NS-398, enhances the effect of radiation in vitro and in vivo preferentially on the cells that express cyclooxygenase-2.
    Pyo H, Choy H, Amorino GP, Kim JS, Cao Q, Hercules SK, DuBois RN.
    Clin Cancer Res; 2001 Oct 15; 7(10):2998-3005. PubMed ID: 11595687
    [Abstract] [Full Text] [Related]

  • 4. Inhibition of cyclooxygenase-2 indirectly potentiates antitumor effects of photodynamic therapy in mice.
    Makowski M, Grzela T, Niderla J, ŁAzarczyk M, Mróz P, Kopeé M, Legat M, Strusińska K, Koziak K, Nowis D, Mrówka P, Wasik M, Jakóbisiak M, Gołab J.
    Clin Cancer Res; 2003 Nov 01; 9(14):5417-22. PubMed ID: 14614028
    [Abstract] [Full Text] [Related]

  • 5. NS-398 inhibits tumor growth and liver metastasis of colon cancer through induction of apoptosis and suppression of the plasminogen activation system in a mouse model.
    Nishikawa M, Stapleton PP, Freeman TA, Gaughan JP, Matsuda T, Daly JM.
    J Am Coll Surg; 2004 Sep 01; 199(3):428-35. PubMed ID: 15325613
    [Abstract] [Full Text] [Related]

  • 6. Inhibited proliferation of cyclooxygenase-2 expressing human hepatoma cells by NS-398, a selective COX-2 inhibitor.
    Hu KQ, Yu CH, Mineyama Y, McCracken JD, Hillebrand DJ, Hasan M.
    Int J Oncol; 2003 Apr 01; 22(4):757-63. PubMed ID: 12632065
    [Abstract] [Full Text] [Related]

  • 7. Cyclooxygenase-2 is a possible target of treatment approach in conjunction with photodynamic therapy for various disorders in skin and oral cavity.
    Akita Y, Kozaki K, Nakagawa A, Saito T, Ito S, Tamada Y, Fujiwara S, Nishikawa N, Uchida K, Yoshikawa K, Noguchi T, Miyaishi O, Shimozato K, Saga S, Matsumoto Y.
    Br J Dermatol; 2004 Aug 01; 151(2):472-80. PubMed ID: 15327557
    [Abstract] [Full Text] [Related]

  • 8. Expression of cyclooxygenase 2 (COX-2) in human glioma and in vitro inhibition by a specific COX-2 inhibitor, NS-398.
    Joki T, Heese O, Nikas DC, Bello L, Zhang J, Kraeft SK, Seyfried NT, Abe T, Chen LB, Carroll RS, Black PM.
    Cancer Res; 2000 Sep 01; 60(17):4926-31. PubMed ID: 10987308
    [Abstract] [Full Text] [Related]

  • 9. Expression of cyclooxygenase 2 in human malignant melanoma.
    Denkert C, Köbel M, Berger S, Siegert A, Leclere A, Trefzer U, Hauptmann S.
    Cancer Res; 2001 Jan 01; 61(1):303-8. PubMed ID: 11196178
    [Abstract] [Full Text] [Related]

  • 10. Prediction of poor survival by cyclooxygenase-2 in patients with T4 nasopharyngeal cancer treated by radiation therapy: clinical and in vitro studies.
    Chen WC, McBride WH, Chen SM, Lee KF, Hwang TZ, Jung SM, Shau H, Liao SK, Hong JH, Chen MF.
    Head Neck; 2005 Jun 01; 27(6):503-12. PubMed ID: 15772955
    [Abstract] [Full Text] [Related]

  • 11. Expression of cyclooxygenase-2 (COX-2) in hepatocellular carcinoma and growth inhibition of hepatoma cell lines by a COX-2 inhibitor, NS-398.
    Bae SH, Jung ES, Park YM, Kim BS, Kim BK, Kim DG, Ryu WS.
    Clin Cancer Res; 2001 May 01; 7(5):1410-8. PubMed ID: 11350912
    [Abstract] [Full Text] [Related]

  • 12. Antiangiogenic treatment enhances photodynamic therapy responsiveness in a mouse mammary carcinoma.
    Ferrario A, von Tiehl KF, Rucker N, Schwarz MA, Gill PS, Gomer CJ.
    Cancer Res; 2000 Aug 01; 60(15):4066-9. PubMed ID: 10945611
    [Abstract] [Full Text] [Related]

  • 13. Inhibition of cyclooxygenase-2 with NS-398 and the prevention of radiation-induced transformation, micronuclei formation and clonogenic cell death in C3H 10T1/2 cells.
    Bisht KS, Bradbury CM, Zoberi I, Curry HA, Kaushal A, Roti Roti JL, Gius D.
    Int J Radiat Biol; 2003 Nov 01; 79(11):879-88. PubMed ID: 14698956
    [Abstract] [Full Text] [Related]

  • 14. Inhibition of cyclooxygenase-1 and -2 expression by targeting the endothelin a receptor in human ovarian carcinoma cells.
    Spinella F, Rosanò L, Di Castro V, Nicotra MR, Natali PG, Bagnato A.
    Clin Cancer Res; 2004 Jul 15; 10(14):4670-9. PubMed ID: 15269139
    [Abstract] [Full Text] [Related]

  • 15. Direct evidence for a role of cyclooxygenase 2-derived prostaglandin E2 in human head and neck xenograft tumors.
    Zweifel BS, Davis TW, Ornberg RL, Masferrer JL.
    Cancer Res; 2002 Nov 15; 62(22):6706-11. PubMed ID: 12438270
    [Abstract] [Full Text] [Related]

  • 16. Suppressive effect of selective cyclooxygenase-2 inhibitor on cytokine release in human neutrophils.
    Kimura T, Iwase M, Kondo G, Watanabe H, Ohashi M, Ito D, Nagumo M.
    Int Immunopharmacol; 2003 Oct 15; 3(10-11):1519-28. PubMed ID: 12946449
    [Abstract] [Full Text] [Related]

  • 17. The cyclooxygenase 2-selective inhibitor NS398 inhibits proliferation of oral carcinoma cell lines by mechanisms dependent and independent of reduced prostaglandin E2 synthesis.
    Minter HA, Eveson JW, Huntley S, Elder DJ, Hague A.
    Clin Cancer Res; 2003 May 15; 9(5):1885-97. PubMed ID: 12738747
    [Abstract] [Full Text] [Related]

  • 18. Selective cyclooxygenase (COX)-1 or COX-2 inhibitors control metastatic disease in a murine model of breast cancer.
    Kundu N, Fulton AM.
    Cancer Res; 2002 Apr 15; 62(8):2343-6. PubMed ID: 11956094
    [Abstract] [Full Text] [Related]

  • 19. [Effects of selective cyclooxygenase-2 inhibitor NS-398 on 5-fluorouracil chemotherapy and progression of colon cells: an experimental study].
    Zhang YC, Wang S, Zhang H, Ye YJ, Liang B, Cui ZR.
    Zhonghua Yi Xue Za Zhi; 2004 Apr 02; 84(7):583-6. PubMed ID: 15144595
    [Abstract] [Full Text] [Related]

  • 20. Celecoxib, a selective cyclooxygenase 2 inhibitor, protects against human epidermal growth factor receptor 2 (HER-2)/neu-induced breast cancer.
    Howe LR, Subbaramaiah K, Patel J, Masferrer JL, Deora A, Hudis C, Thaler HT, Muller WJ, Du B, Brown AM, Dannenberg AJ.
    Cancer Res; 2002 Oct 01; 62(19):5405-7. PubMed ID: 12359744
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.